(thirdQuint)Study of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL.

 This study is designed to assess the safety and immunogenicity of DAPTACEL(R) vaccine administered at 4 to 6 years of age according to the US standard of care.

 The study population consists of PENTACEL cent -primed subjects from Aventis Pasteur's pivotal studies 494-01 and 494-03.

 These children will receive DAPTACEL(R) vaccine as a 5th dose immunization between 4 to 6 years of age.

.

 Study of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL@highlight

Objectives: - To present the rates of adverse reactions after a dose of DAPTACEL(R) vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL cent vaccine.

 - To present immunogenicity before and after a single dose of DAPTACEL(R) vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL cent vaccine.

